// App-Quantinova.ai

4539 : Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

Researchers

Presenter

  • Ronac Mamtani

Principal Investigators

  • Thomas Powles

  • Guru P. Sonpavde

  • Yohann Loriot

  • Ignacio Duran

  • Jae-Lyun Lee

  • Nobuaki Matsubara

  • Christof Vulsteke

  • Daniel Castellano

  • Srikala S. Sridhar

  • Helle Pappot

  • Begoa P. Valderrama

  • Howard Gurney

  • Jens Bedke

  • Michiel Simon Van Der Heijden

  • Chunzhang Wu

  • Zsolt Hepp

  • Caroline McKay

  • Daniel P. Petrylak

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Center for Oncological Research (CORE), University of Antwerp, Integrated Cancer Center Ghent, Ghent, Belgium

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

  • Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain

  • Macquarie University Hospital, Sydney, Australia

  • Department of Gynecology, University of Tuebingen, Tuebingen, Tuebingen, Germany

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Astellas Pharma, Inc., Northbrook, IL

  • Seagen, Inc., Bothell, WA

  • Astellas Pharma, Inc., Northbrook, IL

  • Yale University School of Medicine, New Haven, CT

Locations

  • United States

  • United Kingdom

  • France

  • Spain

  • Japan

  • Belgium

  • Canada

  • Denmark

  • Australia

  • Germany

  • Netherlands

Companies

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03474107

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved